Menu

Canadian Association of Gastroenterology Position Statement on the Use of Thiopurines in the Treatment of Inflammatory Bowel Disease

John K. Marshall MD1, Anthony R. Otley MD2, Waqqas Afif MD3, Charles N. Bernstein MD4, Lawrence Hookey MD5, Grigorios Leontiadis MD1, Remo Panaccione MD6, Brian Bressler MD7

July 2014

Canadian Association of Gastroenterology position statement: Fecal microbiota transplant therapy

Paul Moayyedi BSc MB ChB PhD MPH FRCP FRCPC AGAF FACG*, John K Marshall MD MSc FRCPC AGAF*, Yuhong Yauan MD PhD, Richard Hunt MB FRCP FRCPC MACG AGAG

February 2014

Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics

Shane M Devlin MD1*, Brian Bressler MD2*, Charles N Bernstein MD3, Richard N Fedorak MD4,
Alain Bitton MD5, Harminder Singh MD3, Brian G Feagan MD6

October 2013

Hip fracture and proton pump inhibitor therapy – a 2013 update

Paul Moayyedi, Yuhong Yuan, Grigorios Leontiadis on behalf of the CAG Clinical Affairs.

August 2013

Canadian Association of Gastroenterology position statement on screening individuals at average risk for developing colorectal cancer: 2010

Desmond J Leddin MB FRCPC1, Robert Enns MD FRCPC2, Robert Hilsden MD FRCPC3 , Victor Plourde MD PhD4,  Linda Rabeneck MD MPH FRCPC5, Daniel C Sadowski MD FRCPC6, Harminder Singh MD FRCPC7

December 2010

Proton Pump Inhibitors and Clopidogrel – What is the current status?

Dan Sadowski, Past VP Clinical Affairs, CAG
Rob Enns, VP Clinical Affairs, CAG
Paul Moayyedi, McMaster University

April 2010

FDA Safety Alert: Oral Sodium Phosphate (OSP) Products for Bowel Cleansing

January 2009

CAG Position Statement: Hip fracture and proton pump inhibitor therapy

Paul Moayyedi for the CAG Clinical Affairs Committee

August 2008

Propofol use for sedation during endoscopy in adults: A Canadian Association of Gastroenterology position statement

Michael F Byrne MA MD (Cantab) MRCP FRCPC1, Naoki Chiba MD MSc FRCPC2, Harminder Singh MD MPH FRCPC3,Daniel C Sadowski MD FRCPC4, for the Clinical Affairs Committee of the Canadian Association of Gastroenterology

May 2008

Community-acquired pneumonia and acid-suppressive drugs: Position statement

CAG Clinical Affairs Committee

February 2006

Clostridium difficile-associated diarrhea (CDAD) and proton pump inhibitor therapy: CAG Position Statement

Canadian Association of Gastroenterology, Clinical Affairs

June 2005

CAG Anti-TNF Therapy: Position Statement

Des Leddin MB, FRCPC
President Elect, CAG

May 2002

CAG - Industry Interaction: Position Statement

January 2002